VBI Vaccines Inc  

(Public, NASDAQ:VBIV)   Watch this stock  
Find more results for David Wilde
+0.07 (3.07%)
Oct 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.34 - 2.35
52 week 1.90 - 3.97
Open 2.35
Vol / Avg. 3,580.00/12,804.00
Mkt cap 45.67M
P/E     -
Div/yield     -
EPS -0.91
Shares 20.03M
Beta 2.34
Inst. own 72%
Sep 10, 2015
VBI Vaccines Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1192.29% -
Operating margin -1109.33% -
EBITD margin - -
Return on average assets -111.32% -176.82%
Return on average equity -167.68% -
Employees 60 -
CDP Score - -


222 3rd St Ste 2241
CAMBRIDGE, MA 02142-1259
United States - Map
+1-617-8303031 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


VBI Vaccines Inc., formerly Paulson Capital Corp., is a biopharmaceutical company. The Company is engaged in the formulation, development and delivery of vaccines that expand and enhance vaccine protection. The Company's eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. The company's lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. The Company has initiated work for manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. The company's Lipid Particle Vaccine technology (LPV) is a vaccine formulation technology that enables the thermostabilization of vaccines through a formulation and freeze-drying process. The company has completed proof of concept thermostability studies on a number of vaccine and biologic targets.

Officers and directors

Steven H. Gillis Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Jeff R Baxter Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Egidio Nascimento CA Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
David E. Anderson Ph.D. Chief Scientific Officer
Age: 45
Bio & Compensation  - Reuters
T. Adam Buckley Vice President - Operations and Project Management
Age: 39
Bio & Compensation  - Reuters
Marc J. Kirchmeier Ph.D. Vice President - Formulations
Bio & Compensation  - Reuters
Sam Chawla Director
Age: 40
Bio & Compensation  - Reuters
Trent Donald Davis Director
Age: 47
Bio & Compensation  - Reuters
Michael Steinmetz Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Alan P. Timmins Independent Director
Age: 55
Bio & Compensation  - Reuters